Articles tagged with Fatty Liver Disease
A six-month treatment with tesamorelin lowered liver fat modestly but significantly in HIV patients. The drug's impact on glucose metabolism was temporary, and reduced liver inflammation may result from lower fat levels.
A study published in Cell Metabolism reveals that free radical molecules contribute to the development of type 2 diabetes, obesity, and fatty liver disease by inactivating protein tyrosine phosphatases. This inactivation leads to a cascade of events promoting disease progression.
Scientists discovered that blocking GLUT8, a molecule carrying large amounts of fructose into liver cells, prevents fatty livers in mice. The study suggests the liver acts as a sink for processing fructose, potentially harming overall metabolic syndrome.
Research found that snacking on high-fat and high-sugar foods increases intrahepatic triglyceride content and belly fat, but not with larger meal size. The study suggests cutting down on snacking may reduce the prevalence of non-alcoholic fatty liver disease.
Bariatric surgery resolves liver inflammation and reverses early-stage liver fibrosis by reducing fat deposits in the liver. The procedure showed significant improvement in nonalcoholic fatty liver disease (NAFLD) in severely obese patients.
Researchers found that lean patients with nonalcoholic fatty liver disease (NAFLD) had a higher overall mortality rate and were more likely to be male and of lower socioeconomic status. They also showed signs of liver inflammation despite having less body fat and lower levels of liver damage.
A UK study found a genetic variant associated with fatty liver disease severity in pediatric patients. Patients had low vitamin D blood levels throughout the year, and most samples were deficient or insufficient in vitamin D status compared to national health standards.
Two studies confirmed NAFLD as an independent cardiovascular risk factor, increasing the risk of atherosclerosis and carotid plaques. Improvement in liver health through treatment is associated with a reduced risk of developing diabetes.
A meta-analysis published in the European Journal of Clinical Nutrition found that fructose is not responsible for the increase in non-alcoholic fatty liver disease. The study suggests that excess calorie consumption, regardless of source, contributes to the development of the disease. Dr. John Sievenpiper, lead author of the study, em...
Johns Hopkins researchers identified a protein called SCAP that regulates fatty liver disease and diabetes. They found that SCAP's 'chauffeur' role is crucial to the cycle of fat production, and disrupting this process may lead to new treatments.
A research team at CNIO has identified AP-1 proteins as key regulators of fatty liver disease (FLD), a condition that affects up to 30% of adults in Western societies. Increased expression of these proteins can prevent fat accumulation and FLD in mice.
A new study published in Gastroenterology found that high-calorie diets, regardless of sugar type, contribute to the development of nonalcoholic fatty liver disease. The study revealed comparable effects of fructose and glucose on the liver, highlighting calorie intake as a key factor in liver disease progression.
Research published in Hepatology suggests that estrogen has a protective effect against the development of severe liver fibrosis in patients with nonalcoholic steatohepatitis (NASH). The study found that men and post-menopausal women have similar risks of developing severe fibrosis compared to pre-menopausal women.
A new imaging technique, MRE, can accurately detect fibrosis in children with chronic liver disease, including non-alcoholic fatty liver disease. The study showed high accuracy in detecting advanced fibrosis in obese patients, potentially reducing the need for costly and invasive liver biopsies.
Researchers at Duke University Medical Center found that increased caffeine intake may reduce fatty liver in people with non-alcoholic fatty liver disease. Consuming four cups of coffee or tea a day could be beneficial in preventing and protecting against the progression of NAFLD.
Researchers found that weight loss surgery can reverse the symptoms of nonalcoholic fatty liver disease by altering DNA methylation and gene expression. This study provides insight into the mechanisms behind bariatric surgery's benefits beyond weight loss.
Penn State researchers found that cocoa powder supplement reduced inflammation and fatty liver disease in mice fed high-fat diet. The study suggests cocoa's polyphenolic compounds may improve gut barrier function and reduce insulin levels.
A study found that non-alcoholic fatty liver disease (NAFLD) is an independent predictor of early atherosclerosis and 10-year cardiovascular risk. Patients with NAFLD had higher carotid intima-media thickness and Framingham score, indicating increased cardiovascular risk.
Researchers have developed a non-invasive test for diagnosing non-alcoholic steatohepatitis (NASH), a more advanced form of NAFLD. The phosphorus magnetic resonance spectroscopy (31P-MRS) technique shows fair diagnostic accuracy for NASH and could improve clinical procedures.
Scientists have discovered that dietary medium chain triglycerides (MCT) can prevent the development of nonalcoholic fatty liver disease (NAFLD) in patients with obesity and type II diabetes. MCT substitution for polyunsaturated fat reduces liver fat accumulation and progression of injury, suggesting a potential future therapy.
Researchers have identified a gene variant ID associated with non-alcoholic fatty liver disease (NAFLD) diagnosis, including steatosis, steatohepatitis, and fibrosis. The study suggests that screening for this variant could lead to earlier detection and improved management of NAFLD.
Patients with nonalcoholic fatty liver disease (NAFLD) without advanced fibrosis do not have higher mortality risk, according to new research. However, those likely to progress to advanced fibrosis had a 69% increase in mortality compared to those without fibrosis.
Scientists from Scripps Research Institute have developed a synthetic compound that reverses the effects of fatty liver disease by suppressing lipid production in the liver. The compound, SR9238, also significantly lowered total cholesterol levels and reduced markers for liver damage.
Researchers have discovered a gene called BAF60c that plays a crucial role in converting dietary carbohydrates into fat. The study found that mice with the disabled gene did not produce excess fat despite eating a high-carb diet.
Scientists have created a new laboratory opossum model to study nonalcoholic steatohepatitis (NASH), a common liver disease affecting up to 15 million Americans. The study found that high responders carried a mutated ABCB4 gene, leading to cholesterol accumulation in the liver and potential development of NASH.
The guidelines provide evidence-based information for diagnosing and managing non-alcoholic fatty liver disease, which is rapidly becoming the most common cause of cirrhosis in the US. The condition can lead to liver cancer and failure, emphasizing the need for standardized medical care.
A new study from VCU School of Medicine has identified molecular changes that may explain the severity of liver disease and risks to heart health in patients with fatty liver. The findings suggest increased cholesterol production and decreased expression of a receptor that takes up cholesterol, leading to cardiovascular disease.
New research published in Hepatology found that moderate exercise does not improve lipoprotein concentrations in obese patients with non-alcoholic fatty liver disease. While exercise reduced intrahepatic triglyceride content, it did not change liver lipoprotein levels or body weight.
A new study explores the progression of diseases leading to liver damage, affecting diverse populations, including young people. The research shows that obesity is putting teens at risk for developing nonalcoholic fatty liver disease, which may lead to lifelong problems and serious consequences.
A University of Illinois study found that soy protein reduces triglycerides and fat accumulation in the liver of obese rats. The researchers believe that soy protein isolate can alleviate the symptoms of fatty liver disease by partially restoring a key signaling pathway.
Research published in The Journal of Hepatology found that moderate alcohol consumption can reduce the risk and severity of liver disease in patients with nonalcoholic fatty liver disease (NALFD). Patients with NALFD who consume two drinks or less daily are half as likely to develop hepatitis as non-drinkers, experiencing less severe l...
A study presented at the International Liver Congress 2012 suggests that gut microbiota transplantation can prevent the development of type 2 diabetes and non-alcoholic fatty liver disease. The study found that transplanting microbiota from healthy mice prevented insulin resistance and liver inflammation in germ-free mice.
A large-scale Danish study has found a positive link between childhood obesity and the development of liver cancer (hepatocellular carcinoma) in adulthood. The study monitored over 165,000 participants and found that as BMI increased during childhood, so did the risk of developing HCC.
A new study by Yale School of Medicine researchers found that obese youths with particular genetic variants are more susceptible to fatty liver disease. The study focused on three ethnic groups and measured liver fat content using magnetic resonance imaging.
Research finds Patatin-like phospholipase domain containing protein-3 (PNPLA3) and glucokinase regulatory protein (GCKR) genetic variants contribute to fatty liver disease in obese children, explaining up to 39% of hepatic fat content.
Research published in Hepatology found that moderate coffee consumption decreases the risk of advanced fibrosis in NASH patients. The study also showed a significant correlation between coffee intake and reduced risk of hepatic fibrosis, particularly among patients with NASH stage 0-1.
A study in zebrafish reveals that a gene mutation affects ketone body transport, leading to lipid accumulation in the liver. This discovery provides new insights into nonalcoholic fatty liver disease (NAFLD) and its link to energy metabolism.
Patients with cirrhosis are more likely to be Hispanic, have lower education, and higher healthcare utilization. They also experience significant functional disability, requiring twice the amount of informal caregiving as non-cirrhotic peers.
Nonalcoholic steatohepatitis (NASH) is rapidly increasing in the U.S., mainly related to obesity and diabetes. Researchers found excellent post-transplantation survival rates among NASH patients, with one-year survival rates near 88%.
Researchers found that patients with fatty livers burn more fat and produce glucose faster than those with healthy livers, potentially leading to organ damage. The study's findings challenge previous assumptions about the role of metabolism in fatty liver disease.
A new study by Johns Hopkins researchers found no correlation between non-alcoholic fatty liver disease (NAFLD) and increased mortality. NAFLD, prevalent among those with heart disease and obesity, does not appear to undermine health and longevity.
Patients with non-alcoholic fatty liver disease (NAFLD) have a lower incidence of liver-related complications and hepatocellular carcinoma compared to those infected with hepatitis C virus. NAFLD patients also had similar mortality rates as patients with HCV, despite having higher rates of cardiovascular complications.
Researchers from the University of Missouri-Columbia found that negative physiological changes associated with type 2 diabetes occur in people who transition from high activity levels to inactivity. Adding regular movement to daily routines can help prevent chronic diseases and weight gain, even if it doesn't lead to visible changes.
Kezhong Zhang is studying CREBH's role in regulating NAFLD through a $1.7 million NIH grant. He aims to understand how CREBH controls fat production and digestion, with implications for preventing and treating NAFLD.
The Research Institute of the McGill University Health Centre (RI-MUHC) has been awarded a $1.4M grant to develop Personalized Medicine for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH). The project aims to identify new biomarkers and disease predictors to improve diagnosis and treatment options.
A new study published in JAMA found that neither vitamin E nor the diabetes drug metformin successfully reduced liver enzymes in children and teens with nonalcoholic fatty liver disease. However, a biopsy of the liver showed improvement in injury pattern with vitamin E therapy in patients with severe fatty liver disease. The study high...
A study funded by NIH found that vitamin E improved the most severe form of fatty liver disease in children, reversing NASH in at least half. The treatment showed significant reductions in liver cell death and improvements in liver enzyme levels.
A randomized controlled trial found that vitamin E and metformin did not demonstrate significant efficacy in reducing liver disease severity or improving insulin resistance in children. The study suggests that lifestyle modification is crucial, while further research into non-invasive markers is warranted.
Researchers found that walking for one hour a day improved insulin sensitivity, increased adiponectin levels, and reduced oxidative damage in obese individuals with prediabetes. This exercise regimen may help slow the progression of nonalcoholic fatty liver disease.
Daily walks increase insulin sensitivity, improve liver health marker PUI, and boost hormone adiponectin levels, linked to fat-burning effects. The study suggests exercise as a medicine for managing non-alcoholic fatty liver disease.
A new study has identified a molecular switch, TBL1, that appears to be a common feature in the development of fatty liver disease. The discovery is consistent with data from human patients and suggests an underlying explanation for the condition.
New data show that NAFLD prevalence in the US is expected to increase by 50% by 2030, driven by rising obesity and diabetes rates. The condition can progress to advanced liver disease, significantly impacting mortality rates.
Researchers discovered new genetic variants affecting nonalcoholic fatty liver disease (NAFLD), which may help doctors diagnose and treat the condition more effectively. The study found that approximately one quarter of NAFLD variation is influenced by genetics, with potential applications for clinical algorithms and novel therapeutics.
UCSF researchers have discovered a crucial hormone pathway that contributes to the development of fatty liver disease. By disrupting this pathway, they found that fat accumulation in the liver can occur even without alcohol consumption. The study's findings may lead to the development of new therapeutic drugs targeting this pathway.
A study by St. Michael's Hospital researchers found that people with fatty liver disease are three times more likely to suffer a stroke than those without the condition. High levels of liver enzymes were also found in adults who had an acute stroke, suggesting a potential link between the two.
Researchers at Mayo Clinic have found that mortality rates from liver diseases are underestimated, with the condition ranking as high as fourth for certain age groups. The study analyzed data from 1979-2006 and found a significant correlation between national statistics and local mortality data.
Researchers found a strong association between obesity and an increased risk of liver cancer, as well as adenoma recurrence in patients with colorectal polyps. Additionally, studies revealed that inflammatory bowel disease is an independent risk factor for coronary artery disease.
Research finds pentoxifylline improves NASH, reducing fat and inflammation; vitamin E also shows promise in improving liver histology independently of insulin resistance. Studies suggest new treatment options for overweight individuals with liver disease.
A new mouse model has revealed that a diet high in fructose and trans fats can lead to fatty liver disease with scar tissue. The study also identified potential biomarkers for early detection and suggests therapeutic interventions may reverse or protect against progressive liver damage.
New research presents findings on non-alcoholic fatty liver disease (NAFLD), showing it significantly affects transplant outcomes and highlighting alternative diagnostic methods. A scoring system, known as the NAFLD fibrosis score, also predicts poor outcomes in patients with NAFLD.